Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€29.55

€29.55

-3.790%
-1.0
-3.790%
€37.00

€37.00

 
Latest predictions
€40.00
20.01.21
buy
-
19.01.21
buy
-
07.01.21
€40.00
06.01.21
buy
-
01.01.21
buy
€45.00
30.12.20
buy
Your prediction

Evotec AG Stock

Evotec AG took a tumble today and lost -€1.000 (-3.790%).
The stock is one of the favorites of our community with 29 Buy predictions and 3 Sell predictions.
As a result the target price of €37.00 shows a positive potential of 25.212% compared to the current price of €29.55 for Evotec AG.
For the coming years our community has positive and negative things to say abot the Evotec AG stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Pros and Cons of Evotec AG in the next few years

Pros
4
Revenue growth >5% per year expected
3
Medium risks for its business
3
Fair valuation
Cons
1
Few uniques
1
Risky balance sheet

Performance of Evotec AG vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Evotec AG -3.790% -8.030% -10.940% 35.055% -1.958% 106.643% 803.946%
MorphoSys AG 1.060% -1.750% -15.331% -17.086% -12.641% 3.224% 97.646%
Nektar Therapeutics -3.640% -0.415% 11.804% 7.452% 26.000% - -
Ionis Pharmaceuticals Inc. 3.120% 2.062% -11.322% -6.954% -4.835% 3.772% 16.399%

Comments

Buy Evotec AG

Sell Evotec AG

Buy Evotec AG

Other discussions about Evotec AG Stock

Trading Evotec AG

Trading Evotec AG

New thread Forum

News

DGAP-News: EVOTEC AND RAPPTA THERAPEUTICS ENTER DISCOVERY AND DEVELOPMENT PARTNERSHIP FOCUSED ON ONCOLOGY TARGET: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: EVOTEC AND RAPPTA THERAPEUTICS ENTER DISCOVERY AND DEVELOPMENT PARTNERSHIP FOCUSED ON ONCOLOGY TARGET
DGAP-News: EVOTEC AND RAPPTA THERAPEUTICS ENTER DISCOVERY AND DEVELOPMENT PARTNERSHIP FOCUSED ON ONCOLOGY TARGET
DGAP-News: EVOTEC PRESENTS GROWTH DRIVERS OF 'AUTOBAHN TO CURES' AT CAPITAL MARKETS DAY: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: EVOTEC PRESENTS GROWTH DRIVERS OF 'AUTOBAHN TO CURES' AT CAPITAL MARKETS DAY
DGAP-News: EVOTEC PRESENTS GROWTH DRIVERS OF 'AUTOBAHN TO CURES' AT CAPITAL MARKETS DAY
DGAP-News: EVOTEC AND STORM THERAPEUTICS LEVERAGE INDIGO PLATFORM TO PROGRESS ONCOLOGY PROJECT TOWARDS CLINICAL STUDIES: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: EVOTEC AND STORM THERAPEUTICS LEVERAGE INDIGO PLATFORM TO PROGRESS ONCOLOGY PROJECT TOWARDS CLINICAL STUDIES
DGAP-News: EVOTEC AND STORM THERAPEUTICS LEVERAGE INDIGO PLATFORM TO PROGRESS ONCOLOGY PROJECT TOWARDS CLINICAL STUDIES